Molecular Formula | C27H26N6O3 |
Molar Mass | 482.53 |
Density | 1.25±0.1 g/cm3(Predicted) |
Melting Point | 149-151°C |
Boling Point | 756.4±60.0 °C(Predicted) |
Flash Point | 411.245°C |
Solubility | DMSO (Slightly, Sonicated), Methanol (Very Slightly, Sonicated) |
Vapor Presure | 0mmHg at 25°C |
Appearance | Solid |
Color | White to Pale Beige |
pKa | 4.21±0.10(Predicted) |
Storage Condition | Keep in dark place,Inert atmosphere,Room temperature |
Refractive Index | 1.64 |
Use | 3-[[[2-[[(4-cyanophenyl) amino] methyl]-1-methyl-1H-benzimidazol-5-yl] carbonyl] pyridine-2-ylamino] ethyl propionate is mainly used as a pharmaceutical intermediate. 3-[[[2-[[(4-cyanophenyl) amino] methyl]-1-methyl-1H-benzimidazol-5-yl] carbonyl] pyridine-2-ylamino] ethyl propionate white to white powder, anticoagulant; used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation Intermediate of the raw material drug dabigatran etexide; dabigatran intermediate; it is a new type of synthetic direct thrombin inhibitor, a prodrug of dabigatran, and a non-peptide thrombin inhibitor. |
application | 3-[[[2-[[(4-cyanophenyl) amino] methyl]-1-methyl-1H-benzimidazol-5-yl] carbonyl] pyridine-2-ylamino] ethyl propionate can be used as an intermediate in organic synthesis and a pharmaceutical intermediate, and can be used in laboratory research and development processes and chemical and pharmaceutical synthesis processes. |